Table 1. Baseline Characteristics of the 19 Included Studiesa.
| Source | Study type | No.b | Age, mean (range), yc | Women, No. (%) | T stage (No. patients) | MINORS criteria score | |||
|---|---|---|---|---|---|---|---|---|---|
| Patients with dnSCC | Patients with IPSCC | dnSCC | IPSCC | dnSCC | IPSCC | ||||
| Direct comparative studies | |||||||||
| Lavertu et al18 | Cohort study | 38 | 10 | 60.3 (23-80) | NA | NA | T1 (3), T2 (9), T3 (20), T4 (16) for both cohorts | NA | 16 |
| de Almeida et al17 | Cohort study | 21 | 13 | 57.0 (SD, 13) | NA | NA | T1 (0), T2 (1), T3 (2), T4 (18) | T1 (2), T2 (2), T3 (2), T4 (7) | 17 |
| Lobo et al6 | Cohort study | 88 | 29 | 63.5 (NA) | 32 (36) | 10 (34) | T1 (8), T2 (10), T3 (9), T4 (52), Tx (9) | T1 (3), T2 (4), T3 (4), T4 (11), Tx (7) | 16 |
| Yan et al19 | Cohort study | 28 | 38 | mean (SD), 62.5 (13.2) for dnSCC, 59.9 (11.5) for IPSCC | 13 (46) | 13 (34) | T1 (7), T2 (4), T3 (6), T4 (11) | T1 (14), T2 (5), T3 (7), T4 (10), Tx (2) | 19 |
| Yu et al20 | Cohort study | 65 | 21 | mean (SD), 58.8 (12.8) for dnSCC, 60.9 (10.3) for IPSCC | 17 (26) | 4 (19) | T1 (3), T2 (9), T3 (22), T4 (31) | T1 (4), T2 (5), T3 (6), T4 (6) | 17 |
| Only dnSCC | |||||||||
| Haraguchi30 | Case series | 15 | 0 | 55.1 | 2 (13) | 0 | NA | T1 (0), T2 (0), T3 (0), T4 (0) | 7 |
| Dulguerov et al28 | Cohort study | 126 | 0 | 56.7 (9-86) | NA | 0 | T1 (18), T2 (26), T3 (27), T4 (52) | T1 (0), T2 (0), T3 (0), T4 (0) | 11 |
| Only IPSCC | |||||||||
| Hug et al32 | Case series | 0 | 18 | 54.5 (21-73) | 0 | 5 (28) | T1 (0), T2 (0), T3 (0), T4 (0) | NA | 8 |
| Lesperance et al36 | Case series | 0 | 14 | 67.0 (51-82) | 0 | 2 (14) | T1 (0), T2 (0), T3 (0), T4 (0) | T1-T3 (7), T4 (7) | 12 |
| Buiret et al25 | Case series | 0 | 11 | 60.0 (42-79) | 0 | 3 (27) | T1 (0), T2 (0), T3 (0), T4 (0) | T1 (2), T2 (1), T3 (5), T4 (3) | 9 |
| Choi et al26 | Case series | 0 | 18 | 59.4 (42-86) | 0 | 4 (22) | T1 (0), T2 (0), T3 (0), T4 (0) | T1 (5), T2 (2), T3 (8), T4 (3) | 11 |
| Kim et al34 | Cohort study | 0 | 16 | 56.5 (31-74) | 0 | 1 (6) | T1 (0), T2 (0), T3 (0), T4 (0) | T1 (1), T2 (4), T3 (2), T4 (9) | 10 |
| Hong et al31 | Cohort study | 0 | 17 | 55.9 (35-77) | 0 | 1 (6) | T1 (0), T2 (0), T3 (0), T4 (0) | T1 (1), T2 (3), T3 (8), T4 (5) | 10 |
| Yu et al46 | Cohort study | 0 | 32 | 56.5 (NA) | 0 | 7 (22) | T1 (0), T2 (0), T3 (0), T4 (0) | T1 (3), T2 (10), T3 (16), T4 (3) | 11 |
| Liang et al39 | Cohort study | 0 | 87 | 54.0 (17-80) | 0 | 23 (26) | T1 (0), T2 (0), T3 (0), T4 (0) | T1 (2), T2 (12), T3 (30), T4 (43) | 10 |
| Karligkiotis et al33 | Cohort study | 0 | 34 | 60.2 (34-80) | 0 | 11 (32) | T1 (0), T2 (0), T3 (0), T4 (0) | T1 (11), T2 (7), T3 (11), T4 (5) | 12 |
| Yasumatsu et al45 | Case series | 0 | 15 | 61.0 (39-81) | 0 | 7 (47) | T1 (0), T2 (0), T3 (0), T4 (0) | T1 (2), T2 (3), T3 (6), T4 (4) | 10 |
| Li et al38 | Cohort study | 0 | 120 | 54.8 (17-82) | 0 | 33 (28) | T1 (0), T2 (0), T3 (0), T4 (0) | T1 (0), T2 (32), T3 (36), T4 (52) | 11 |
| Li et al37 | Cohort study | 0 | 21 | 59.2 (35-81) | 0 | 3 (14) | T1 (0), T2 (0), T3 (0), T4 (0) | T1 (2), T2 (1), T3 (10), T4 (8) | 12 |
Abbreviations: dn, de novo; IP, inverted papilloma; MINORS, methodological index for nonrandomized studies; NA, not available; SCC, squamous cell carcinoma; T, tumor.
a
Table is divided into studies that directly compare between patients with dnSCC and IPSCC, studies of patients with only dnSCC, and studies of patients with only IPSCC.
b
No. indicates cohort size.
c
Values written as mean (range) unless otherwise indicated.